Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Genfit is a biotechnology business based in the US. Genfit stocks (GNFT.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.8 – a decrease of 0.52% over the previous week. Genfit employs 130 staff and has a trailing 12-month revenue of around $7.8 million.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Since the stock market crash in March caused by coronavirus, Genfit's stock price has had significant negative movement.
Its last market close was $3.84, which is 78.50% down on its pre-crash value of $17.86 and 153.39% down on the lowest point reached during the March crash when the stocks fell as low as $9.73.
If you had bought $1,000 worth of Genfit stocks at the start of February 2020, those stocks would have been worth $868.19 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $219.19.
|Latest market close||$3.84|
|52-week range||$3.5 - $6.15|
|50-day moving average||$3.8594|
|200-day moving average||$4.1359|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-3.065|
Note: The dollar amounts in the table below are in Canadian dollars.
|1 week (2021-09-17)||-0.52%|
|1 month (2021-08-25)||3.78%|
|3 months (2021-06-25)||-1.59%|
|6 months (2021-03-25)||-17.60%|
|1 year (2020-09-25)||-8.35%|
|2 years (2019-09-25)||-76.73%|
|Revenue TTM||USD$7.8 million|
|Gross profit TTM||USD$7.8 million|
|Return on assets TTM||-19.06%|
|Return on equity TTM||-298.13%|
|Market capitalisation||USD$178.4 million|
TTM: trailing 12 months
There are currently 9,199 Genfit stocks held short by investors – that's known as Genfit's "short interest". This figure is 2% down from 9,385 last month.
There are a few different ways that this level of interest in shorting Genfit stocks can be evaluated.
Genfit's "short interest ratio" (SIR) is the quantity of Genfit stocks currently shorted divided by the average quantity of Genfit stocks traded daily (recently around 8760.9523809524). Genfit's SIR currently stands at 1.05. In other words for every 100,000 Genfit stocks traded daily on the market, roughly 1050 stocks are currently held short.
However Genfit's short interest can also be evaluated against the total number of Genfit stocks, or, against the total number of tradable Genfit stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Genfit's short interest could be expressed as 0% of the outstanding stocks (for every 100,000 Genfit stocks in existence, roughly 0 stocks are currently held short) or 0.0002% of the tradable stocks (for every 100,000 tradable Genfit stocks, roughly 0 stocks are currently held short).
Such a low SIR usually points to an optimistic outlook for the stock price, with fewer people currently willing to bet against Genfit.
Find out more about how you can short Genfit stock.
We're not expecting Genfit to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.
Over the last 12 months, Genfit's stocks have ranged in value from as little as $3.5 up to $6.15. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Genfit's is 1.1357. This would suggest that Genfit's stocks are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.
Everything we know about the GTY Technology IPO, plus information on how to buy in. Read more…
We look at 6 popular stock discussion groups from Canada and overseas.Read more…
We’ve rounded up the top dividend stocks in Canada. Check out current stock prices, historical stock performance, company info and more.Read more…
Steps to owning and managing China Evergrande Group shares from Canada.
Everything we know about the Planet Labs IPO, plus information on how to buy in.
Everything we know about the Impossible Foods IPO, plus information on how to buy in.
Everything we know about the Samsara IPO, plus information on how to buy in.
Everything we know about the Allbirds IPO, plus information on how to buy in.
This guide will show you step-by-step instructions on how to buy the Smooth Love Potion (SLP) token as well as a list of exchanges you can trade it on.
Everything we know about the OnlyFans IPO, plus information on how to buy in.
Ever wondered how to buy shares in Vinco Ventures? We explain how and compare a range of providers that can give you access to many brands, including Vinco Ventures.
Steps to owning and managing Weber Inc. stocks, with 24-hour and historical pricing before you buy.
Everything we know about the Chobani IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.